Rao Gayatri, Patel Prem S, Idler Suji P, Maloof Paul, Gascon Pedro, Potian Julius A, Rameshwar Pranela
Department of Medicine-Hematology/Oncology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, New Jersey, USA.
Cancer Res. 2004 Apr 15;64(8):2874-81. doi: 10.1158/0008-5472.can-03-3121.
Despite early detection of breast cancer, patients' survival may be compromised if the breast cancer cells (BCCs) enter the bone marrow (BM). It is highly probable that BCCs enter the BM long before clinical detection. An in vitro coculture model with BM stroma and BCCs (cell lines; primary cells from stage III BC, n = 7, and stage M0, n = 3) mimicked early entry of BCCs into the BM. In coculture, BCCs exhibit contact inhibition and do not require otherwise needed growth supplements. Stromal growth rate was increased 2-fold in coculture. The inclusion of BCCs in stromal support of long-term culture-initiating cell assay frequencies show no difference (38 +/- 3 versus 36 +/- 6). Nontumorigenic breast cells (patients and cell lines) did not survive in coculture, suggesting that the model could select for malignant population in surgical breast tissues. Cocultures were able to select cells with 73 +/- 7% cloning efficiencies and with the ability to form cocultures with BM stroma. Preprotachykinin-I (PPT-I), a gene that is conserved by evolution, facilitates BCC integration as part of the stromal compartment. This was deduced as follows: (a) nontumorigenic breast cells (n = 4) genetically engineered to express PPT-I and led to anchorage-independent growth, foci formation, and formation of cocultures; and (b) suppression of PPT-I in BCCs (n = 5) with pPMSKH1-PPT-I small interfering RNA reverted the cells to nontumorigenic phenotypes and was undetectable in the BM nude mice. The evidence supports that the PPT-I gene facilitates the integration of BCCs in the stromal compartment during a period before clinical detection, without disrupting hematopoietic activity.
尽管乳腺癌能够早期发现,但如果乳腺癌细胞(BCCs)进入骨髓(BM),患者的生存可能会受到影响。很有可能BCCs在临床检测之前很久就已进入骨髓。一种将骨髓基质与BCCs(细胞系;来自III期乳腺癌的原代细胞,n = 7,以及M0期,n = 3)进行体外共培养的模型模拟了BCCs早期进入骨髓的情况。在共培养中,BCCs表现出接触抑制,并且不需要其他所需的生长补充剂。共培养时基质生长速率提高了2倍。在长期培养起始细胞分析频率的基质支持中加入BCCs显示没有差异(38 +/- 3对36 +/- 6)。非致瘤性乳腺细胞(患者和细胞系)在共培养中无法存活,这表明该模型可以筛选出手术乳腺组织中的恶性细胞群体。共培养能够筛选出克隆效率为73 +/- 7%且能够与骨髓基质形成共培养的细胞。前速激肽原-I(PPT-I)是一种在进化中保守的基因,它促进BCCs作为基质区室的一部分进行整合。这是通过以下方式推断出来的:(a)经过基因工程改造以表达PPT-I的非致瘤性乳腺细胞(n = 4)导致了不依赖贴壁的生长、病灶形成以及共培养的形成;(b)用pPMSKH1-PPT-I小干扰RNA抑制BCCs(n = 5)中的PPT-I可使细胞恢复为非致瘤性表型,并且在骨髓裸鼠中无法检测到。这些证据支持PPT-I基因在临床检测前的一段时间内促进BCCs在基质区室中的整合,而不会破坏造血活性。